J&J’s Caplyta wins MDD approval to extend revenue horizon
Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.
Caplyta’s MDD label extension marks the first approval since J&J acquired the drug in a $14.6bn buyout.
The partnership is the latest in a long line of AI-centric projects in drug discovery and development.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms,...
Huawei’s three key steps to drive industrial intelligence forward and unleash AI’s full potential
First responders see AI and other advanced tech as essential
What does the EU Data Act mean for businesses?
Trump blames Covid-19 drugmakers for fuelling CDC turmoil